• +1-646-491-9876
    • +91-20-67278686

    Search

    Wounds-Pipeline Review H1 2017

    Wounds-Pipeline Review H1 2017

    • Report Code ID: RW0001834395
    • Category Pharmaceuticals
    • No. of Pages 186
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Wounds - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2017, provides an overview of the Wounds (Dermatology) pipeline landscape.

    Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 58, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 7 molecules, respectively.

    Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology) .
    - The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 6
    List of Figures 7
    Introduction 8
    Publisher Report Coverage 8
    Wounds - Overview 9
    Wounds - Therapeutics Development 10
    Pipeline Overview 10
    Pipeline by Companies 11
    Pipeline by Universities/Institutes 16
    Products under Development by Companies 18
    Products under Development by Universities/Institutes 22
    Wounds - Therapeutics Assessment 23
    Assessment by Target 23
    Assessment by Mechanism of Action 26
    Assessment by Route of Administration 29
    Assessment by Molecule Type 31
    Wounds - Companies Involved in Therapeutics Development 33
    AlgiPharma AS 33
    Alliance Pharma Plc 33
    AmpliPhi Biosciences Corp 33
    AndroScience Corp 34
    Anterogen Co Ltd 34
    Aridis Pharmaceuticals LLC 35
    Beech Tree Labs Inc 35
    Bio3 Research Srl 35
    Biotec Pharmacon ASA 36
    Blueberry Therapeutics Ltd 36
    Cellphire Inc 36
    Chiesi Farmaceutici SpA 37
    CorMedix Inc 37
    Dermala Inc 38
    Destiny Pharma Ltd 38
    Escape Therapeutics Inc 38
    EyeGene Inc 39
    FibroGen Inc 39
    Foresee Pharmaceuticals LLC 40
    Gene Signal International SA 40
    GlaxoSmithKline Plc 40
    IC-MedTech Inc 41
    Living Cell Technologies Ltd 41
    Madam Therapeutics BV 42
    miRagen Therapeutics Inc 42
    NatureWise Biotech & Medicals Corp 43
    Novan Inc 43
    Octapharma AG 44
    Omeros Corp 44
    Osiris Therapeutics Inc 44
    Pacific Northwest Biotechnology LLC 45
    ProMetic Life Sciences Inc 45
    RMB-Research GmbH 46
    RXi Pharmaceuticals Corp 46
    SomaGenics Inc 47
    Stratatech Corp 47
    Synedgen Inc 47
    Thesan Pharmaceuticals Inc 48
    Topadur Pharma AG 48
    Traverse Biosciences Inc 48
    Tumorend LLC 49
    Vascular BioSciences 49
    viDA Therapeutics Inc 49
    Wounds - Drug Profiles 51
    (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 51
    A-3APO - Drug Profile 52
    ABSA-01 - Drug Profile 54
    AGL-110 - Drug Profile 58
    ALLO-ASC - Drug Profile 59
    AlloGraf - Drug Profile 61
    Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 62
    APO-1 - Drug Profile 63
    APO-2 - Drug Profile 64
    AR-101 - Drug Profile 65
    Arginine Butyrate - Drug Profile 66
    ARN-077 - Drug Profile 67
    ASCJ-9 - Drug Profile 68
    AyuV-25 - Drug Profile 70
    B-244 - Drug Profile 71
    BB-1000 - Drug Profile 73
    BDM-I - Drug Profile 74
    BTL-slo - Drug Profile 77
    CAR Peptide - Drug Profile 79
    Cell Therapy for Dermatology and Immunology - Drug Profile 80
    CM-101 - Drug Profile 82
    CRMD-004 - Drug Profile 83
    CTR-2 - Drug Profile 84
    daprodustat - Drug Profile 85
    DB-2121 - Drug Profile 88
    Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 89
    Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile 90
    Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 91
    EGS-001 - Drug Profile 92
    FG-6874 - Drug Profile 93
    FP-025 - Drug Profile 94
    G-3KL - Drug Profile 95
    Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 96
    Gene Therapy to Activate HSP60 for Wounds - Drug Profile 97
    GS-156 - Drug Profile 98
    Human Growth Factor - Drug Profile 99
    hVGF - Drug Profile 100
    JM-2 CR - Drug Profile 101
    LWnt-3a - Drug Profile 102
    MG-53 - Drug Profile 103
    MMP-26051 - Drug Profile 105
    MMP-26052 - Drug Profile 106
    molgramostim - Drug Profile 107
    Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 108
    MRG-110 - Drug Profile 109
    NBM-67 - Drug Profile 110
    ND-336 - Drug Profile 111
    NTCELL - Drug Profile 112
    Oligomer G for Burn Wounds - Drug Profile 117
    OTI-1011 - Drug Profile 118
    OTI-1502 - Drug Profile 119
    P-148 - Drug Profile 120
    Panaecin - Drug Profile 121
    Peptides for Wounds - Drug Profile 122
    Perlecan - Drug Profile 123
    PGF - Drug Profile 125
    plasminogen (recombinant) - Drug Profile 126
    Polysaccharide for Wounds and Scars - Drug Profile 127
    Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile 128
    Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 129
    Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 130
    Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 131
    Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 132
    Recombinant Protein to Agonize FGFR2 for Wounds - Drug Profile 133
    Recombinant Protein to Agonize NGFR for Wounds - Drug Profile 134
    Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 135
    Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 136
    Recombinant Proteins for Diabetic Wound Healing - Drug Profile 137
    RT-1740 - Drug Profile 138
    SFR-9X0125 - Drug Profile 139
    SG-404 - Drug Profile 140
    silver sulfadiazine - Drug Profile 141
    Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile 142
    Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile 143
    Small Molecule to Target LGR6 for Dermatology - Drug Profile 144
    Small Molecules for Staphylococcal Infections and Wounds - Drug Profile 145
    Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile 146
    Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 147
    Soluble Beta Glucan - Drug Profile 148
    Statmicoll - Drug Profile 151
    Stm Cell Therapy for Chronic Wounds - Drug Profile 152
    Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 153
    Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 154
    Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile 155
    Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 156
    Thrombosomes - Drug Profile 158
    Tolecine - Drug Profile 159
    TOPN-53 - Drug Profile 160
    TRBN-0224 - Drug Profile 161
    TWB-103 - Drug Profile 163
    V-2248 - Drug Profile 164
    VTI-3000 Series - Drug Profile 165
    WH-1 - Drug Profile 166
    XF-70 - Drug Profile 167
    Wounds - Dormant Projects 168
    Wounds - Discontinued Products 173
    Wounds - Product Development Milestones 174
    Featured News & Press Releases 174
    Appendix 179
    Methodology 179
    Coverage 179
    Secondary Research 179
    Primary Research 179
    Expert Panel Validation 179
    Contact Us 179
    Disclaimer 180

    List of Tables

    Number of Products under Development for Wounds, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Wounds - Pipeline by AlgiPharma AS, H1 2017
    Wounds - Pipeline by Alliance Pharma Plc, H1 2017
    Wounds - Pipeline by AmpliPhi Biosciences Corp, H1 2017
    Wounds - Pipeline by AndroScience Corp, H1 2017
    Wounds - Pipeline by Anterogen Co Ltd, H1 2017
    Wounds - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
    Wounds - Pipeline by Beech Tree Labs Inc, H1 2017
    Wounds - Pipeline by Bio3 Research Srl, H1 2017
    Wounds - Pipeline by Biotec Pharmacon ASA, H1 2017
    Wounds - Pipeline by Blueberry Therapeutics Ltd, H1 2017
    Wounds - Pipeline by Cellphire Inc, H1 2017
    Wounds - Pipeline by Chiesi Farmaceutici SpA, H1 2017
    Wounds - Pipeline by CorMedix Inc, H1 2017
    Wounds - Pipeline by Dermala Inc, H1 2017
    Wounds - Pipeline by Destiny Pharma Ltd, H1 2017
    Wounds - Pipeline by Escape Therapeutics Inc, H1 2017
    Wounds - Pipeline by EyeGene Inc, H1 2017
    Wounds - Pipeline by FibroGen Inc, H1 2017
    Wounds - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
    Wounds - Pipeline by Gene Signal International SA, H1 2017
    Wounds - Pipeline by GlaxoSmithKline Plc, H1 2017
    Wounds - Pipeline by IC-MedTech Inc, H1 2017
    Wounds - Pipeline by Living Cell Technologies Ltd, H1 2017
    Wounds - Pipeline by Madam Therapeutics BV, H1 2017
    Wounds - Pipeline by miRagen Therapeutics Inc, H1 2017
    Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H1 2017
    Wounds - Pipeline by Novan Inc, H1 2017
    Wounds - Pipeline by Octapharma AG, H1 2017
    Wounds - Pipeline by Omeros Corp, H1 2017
    Wounds - Pipeline by Osiris Therapeutics Inc, H1 2017
    Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017
    Wounds - Pipeline by ProMetic Life Sciences Inc, H1 2017
    Wounds - Pipeline by RMB-Research GmbH, H1 2017
    Wounds - Pipeline by RXi Pharmaceuticals Corp, H1 2017
    Wounds - Pipeline by SomaGenics Inc, H1 2017
    Wounds - Pipeline by Stratatech Corp, H1 2017
    Wounds - Pipeline by Synedgen Inc, H1 2017
    Wounds - Pipeline by Thesan Pharmaceuticals Inc, H1 2017
    Wounds - Pipeline by Topadur Pharma AG, H1 2017
    Wounds - Pipeline by Traverse Biosciences Inc, H1 2017
    Wounds - Pipeline by Tumorend LLC, H1 2017
    Wounds - Pipeline by Vascular BioSciences, H1 2017
    Wounds - Pipeline by viDA Therapeutics Inc, H1 2017
    Wounds - Dormant Projects, H1 2017
    Wounds - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Wounds - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Wounds - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Wounds - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Wounds - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Wounds, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AlgiPharma AS
    Alliance Pharma Plc
    AmpliPhi Biosciences Corp
    AndroScience Corp
    Anterogen Co Ltd
    Aridis Pharmaceuticals LLC
    Beech Tree Labs Inc
    Bio3 Research Srl
    Biotec Pharmacon ASA
    Blueberry Therapeutics Ltd
    Cellphire Inc
    Chiesi Farmaceutici SpA
    CorMedix Inc
    Dermala Inc
    Destiny Pharma Ltd
    Escape Therapeutics Inc
    EyeGene Inc
    FibroGen Inc
    Foresee Pharmaceuticals LLC
    Gene Signal International SA
    GlaxoSmithKline Plc
    IC-MedTech Inc
    Living Cell Technologies Ltd
    Madam Therapeutics BV
    miRagen Therapeutics Inc
    NatureWise Biotech & Medicals Corp
    Novan Inc
    Octapharma AG
    Omeros Corp
    Osiris Therapeutics Inc
    Pacific Northwest Biotechnology LLC
    ProMetic Life Sciences Inc
    RMB-Research GmbH
    RXi Pharmaceuticals Corp
    SomaGenics Inc
    Stratatech Corp
    Synedgen Inc
    Thesan Pharmaceuticals Inc
    Topadur Pharma AG
    Traverse Biosciences Inc
    Tumorend LLC
    Vascular BioSciences
    viDA Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//wounds-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//wounds-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//wounds-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments